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(57) ABSTRACT 
The present invention relates generally to molecular com 
pounds Which encode the protective M-like protein of Strep 
tococcus equi (SeM), the amino acid compound Which is 
thereby encoded, and compositions of matter Which incor 
porate either the encoding compounds or the cellular com 
ponents for Which they encode. For instance, vaccines Which 
utilize the amino acid compounds or vectors and cell lines 
useful to make the amino acid compounds described herein 
are subjects of the present invention. The present invention 
provides methods to stimulate S. equi-speci?c immune 
response in horses. It also provides diagnostic assays for 
Streptococcus equi. 
6 Claims, 6 Drawing Sheets 
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~55 
1 TACATTCTTGCTTATTAAATAAAAATcACAmTGCATAAAGAAGTTCCTGTCAT‘E 
-10 
61 ETIAAAACTGCCATGAGGTTATAATAGTATGGTAAAACAAAAAAGTGTGCCCATAACGG 
1129s MFLRNNKPKFSIRK 
121 CTTTCACATATGTTTTTGAGAAATAACAAGCCAAAATTTAGCATCAGAAAA 
15 LSACAASVLVATSVLGGTTV 
181 c14401000007004004113710141140110041104401010110004000404401014 
55 KANSEVSRTATPRLSRDLKN 
241 AAAGCGAACTCTGAGGTTAGTCGTACGCCCACTCCAAGATTATCGCGTGATTTAAAAAAT 
55 RLSDIAISGDASSAQKVRNL 
501 AGATTAACCGATATAGCCATAAOTGGAGATGCCTCATCAGCCCAAAAAGTTCGAAATCTT 
75 LKCASVGDLQALLRGLDSAR 
551 CTAAAAGGCGCCTCTGTTCCCGATTTACAGGCATTATTGAGAGGTCTTGATTCAGCAAGG 
95 AAYGRDDYYNLLMHLSSMLN 
421 GCTGCGTATGGTAGAGATGATTATTACAATTTATTGATGCACCTTTCATCGATGTTAAAT 
115 DKPDGDRROLSLASLLVDE] 
481 GATAAACCTCATGCGGATAGAAGACAATTAAGTTTGGCTTCATTACTTGTACATCAAATT 
155 EKRIADGDRYAKLLEAKLAA 
541 044440013041100104100404140014100444407101104000711114011004001 
1551KSOQEMLRERDSQLRNLEK 
501 ATTAAATCTCAACAAGAAATGCTTAGAGAAAGAGATTCCCAACTTCGAAATCTACAGAAG 
175 EKEQELTKAKDERQALTESF 
551 CAGAAAGAACAAGAGCTCACAAAAGCTAAAGATGAGCGTCAAGCTCTTACCGAATCATTC 
195 NKTLSRSTKEYNKLKTELAK 
721 AACAAAACTTTATCAACATCAACAAAACACTATAATAAACTAAAAACAGAACTTCCAAAA 
215 EKEKAAKMTKELADKLSN_A_E 
781 GAAAAAGAAAAAGCAGCTAACATGACTAAGCAATTAGCACATAAGCTAAGCAATGCTGAA 
255 ASRDKAFAVSKDLADKLSSA 
541 00440100104144400011100401410444407111140040414471074401401001 
255 EASRDKAFAVSKDLADKLAA 
901 GAACCAAGTCGTGATAAAGCTTTTGCAGTATCAAAAGATTTAGCAGATAAATTGGCAGCT 
275 KTAEAEKLMENVGSLDRLVE 
951 AAAACAGCAGAAGCTGAAAACTTAATGGAAAACGTTGGTAGTCTAGACCGCTTGCTAGAG 
295 SAKREMAOKLAEIDQLTADK 
1021 TCTGCAAAACGTGAAATGGCTCAAAAATTAGCAGAAATTCATCAATTAACTGCTGATAAG 
515 AKADAELAAANDTIASLQTE 
1081 GCTAAGGCTCATGCACAGCTTCCACCTGCAAATGACACCATTGCATCACTTCAAACACAG 
555 LEKAKTELAVSERLIESGKR 
1 141 01407144440014404040400110010111040400011104110411104000444001 
555 EIAELOKQKDASDKALVESO 
1201 CAAATTGCTCAGCTACAAAAACAAAAAGATGCTTCTCATAAGGCTTTAGTAGAATCACAA 
575 ANVAELEKQKAASDAKVAEL 
1261 CCTAATGTACCAGAGCTTCAAAAACAAAAAGCAGCATCAGATGCTAAGGTAGCAGAGCTT 
395_E_KEVEAAKAEVADLKAQLAK 
1521 GAAAAAGAAGTTGAAGCTGCTAAAGCTGAGGTTCCAGATCTTAAAGCACAATTAGCTAAG 
415 KEEELEAVKKEKEALEAKIE 
1381 AAACAAGAACAGCTTGAACCCGTTAAGAAGGAAAAACAAGCGCTTGAAGCTAAGATTGAA 1 A 
HSQKKAHAEELSKLKEMLEKK - 
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1441 CACCTCAAAAAACCTCATCCTGAGCAACTTTCAAAACTTAAAGAAATGCTTGACAAGAAA 
455 D H A N A D L O A E I N R L K O E L A D 
1501 CACCATGCAAATGCAGATCTTCAAGCAGAAATCAATCGCTTGAAGCAAGAGCTAGCTGAC 
475 R I K S L S Q C C R A S O T N P G T T T 
1561 AGGATTAACTCATTGTCACAACGTGCTCGTCCTTCACAAACAAACCCACGCACTACAACT 
495 A K A D Q L P S T G E S A N P F F T l A 
1621 CCTAAAGCAGGTCAATTCCCATCTACTGCTGACTCTCCTAACCCATTCTTCACTATTOCA 
515 A L T V T A G A G M A V V S P K R K E N 
1681 GCTCTTACTGTCATCGCTGGTGCTGGAATGGCTCTGGTCTCTCCTAAACGCAAAGAAAAC 
1 741 TAAGCTATTTCCTCTTTCCCCAATGCACAATAGCCGAAATAATAGAGCGACTATCGTTKI 
terminator 
1801 AACACAAAAGCAACAGTCTCCTGTCTGTTCCTTTTTGTGATATTWGCTCATCAGTCTA 
1861 OCCTAATGGTTTTCTGCCCTTTATCTCCA (SEQ ID NO:10) 
FIG.1 B 
U.S. Patent 0a. 1, 2002 Sheet 3 0f 6 US 6,458,358 B1 
U.S. Patent 0a. 1, 2002 Sheet 4 0f 6 US 6,458,358 B1 
w 5% ma. 


US 6,458,358 B1 
1 
COMPOUNDS ENCODING THE 
PROTECTIVE M-LIKE PROTEIN OF 
S TREPTOCOCCUS EQUI AND ASSAYS 
THEREFOR 
This application claims priority to US. Provisional 
Patent Application No. 60/050,577, ?led Jun. 24, 1997. 
This invention Was developed under a grant from the 
US. Government: USDA-NRICGP Number 95-01837, and 
therefore, the US. Government may have certain rights in 
this invention. 
BACKGROUND OF THE INVENTION 
The present invention relates generally to molecular com 
pounds Which encode the protective M-like protein of Strep 
tococcus equi (SeM), the amino acid compound Which is 
thereby encoded, and compositions of matter Which incor 
porate either the encoding compounds or the cellular com 
ponents for Which they encode. For instance, vaccines Which 
utiliZe the amino acid compounds or vectors and cell lines 
useful to make the amino acid compounds described herein 
are subjects of the present invention. The present invention 
provides methods to stimulate S. equi-speci?c immune 
response in horses. It also provides diagnostic assays for 
Streptococcus equi. 
Streptococcus equi, a Lance?eld group C streptococcus, 
causes strangles, a highly contagious disease of the 
nasopharynX and draining lymph nodes of Equidae. The 58 
kDa antiphagocytic M-like protein (SeM) is a major viru 
lence factor and protective antigen and functions by limiting 
deposition of C3b on the bacterial surface and by directly 
binding ?brinogen. BoschWitZ and Timoney, 17 Microbiol. 
Pathogenesis 121 (1994) and BoschWitZ and Timoney, 62 
Infect. Imnun. 3515 (1994). 
In the recent past, S. equi outbreaks on horse farms have 
been avoided and treated by quarantine of suspect animals; 
antiseptic handling of food, bedding and housing; and anti 
biotics When indicated. Vaccines comprising avirulent S. 
equi or fractions thereof have been described, but success 
rate has been low. US. Pat. No. 5,183,659 describes a 
vaccine Which stimulated a nasopharyngeal antibody 
response in horses, but the vaccine had a limitation of many 
such vaccines, Which is risk of reversion to virulence and 
occasional abcess development in vaccinated horses. 
S. equi is shed in nasal discharges and pus from lymph 
nodes of affected animals. Routine laboratory detection of 
the bacterium involves bacteriologic culture of nasal sWabs, 
nasal Washes and pus from abscesses and is often dif?cult 
because of background contamination, small numbers of the 
organism, or the presence of S. zooepia'emicus and other 
[3-hemolytic streptococci. Completion of culture and iden 
ti?cation usually takes 2 to 3 days, an excessively lengthy 
interval given the highly contagious nature of strangles and 
the need to quickly identify shedding horses so that they may 
be isolated in the early stages of an outbreak. 
SUMMARY OF THE INVENTION 
It is an object of the present invention to provide molecu 
lar compounds Which encode SeM and compositions of 
matter Which incorporate either the encoding compounds or 
the cellular components for Which they encode. 
It is therefore an object to provide vectors, cell lines and 
cell membrane preparations using the compounds disclosed. 
It is yet another object to provide a method to provide 
assays for detection of Streptococcus equi. 
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2 
Other objects and features of the present invention Win be 
apparent from the folloWing detailed description, examples 
and claims. 
De?nitions 
As used herein, the folloWing terms shall have the cor 
responding meaning set forth. All other terms are intended 
to have the meaning as understood commonly by those in the 
relevant ?eld of art. 
“Biological Sample” means nasal or oral mucus sample or 
blood sample. 
“Transformation” and “transfection” mean to cause 
nucleic acid to enter a cell, Whether or not the nucleic acid 
incorporates into the genome. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The invention Will be further described in conjunction 
With the accompanying draWings, in Which: 
FIG. 1 (SEQ ID NO:10) is the nucleotide and deduced 
amino acid sequence of SeM. Base and amino acid positions 
are shoWn on the left. Putative promoter and ribosomal 
binding sites (RBS) are boXed, and signal and membrane 
anchor sequences are shoWn in bold type. Repeats are 
underlined. 
FIG. 2 is an immunoblot shoWing reactions of a lysate of 
E. coli BL21, SeM02 and a mutanolysin eXtract of S. equi 
With antisera 216 and 963 to SeM and recombinant SeM 
respectively. 
FIG. 3 is an immunoblot shoWing the reactions of 
mutanolysin eXtracts of a series of temporally and geo 
graphically separated isolates of S. equi With antisera to 
recombinant SeM. Estimated molecular masses are shoWn to 
the right of the ?gure. 
FIG. 4 is an immunoblot shoWing linear epitopes recog 
niZed by IgA in nasal Washes of convalescent (8 Weeks) 
horses. 
FIG. 5 is graph illustrating the regions of SeM reactive 
With antibodies in horse sera taken 8 Weeks after recovery 
from strangles. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides nucleic acid compounds 
comprising a compound of the folloWing sequence: 
US 6,458,358 B1 
1 AGCTTTCTGTCACCTGATGGTCCTTATCAAATACTGTAATTGATAACTTCAAACAGCCCT 
6 l GTAGAGATTTTACTAACGACATAGTATCCATGCTAAGCGTCACCCCCTTCATAATCCTCA 
l 2 l CGGTATCTTATTCTATCTTAAAATTTAAGAAAAGCAAGGATATGCACTTATAATGAAAAA 
l 8 l ATAGACATAAAAAACAATAATATACATTCTTGCTTATTAAATAAAAATGACAATGTACTG 
2 4 l CATAAAGAAGTTCCTGTCATTAAAATAAAAGTGCCATGAGGTTATAATAGTATGGTAAAA 
3 O l CAAAAAAGTGTGCCCATAACGGGTAGAGAGGAATTGACATATGTTTTTGAGAAATAACAA 
3 6 l GCCAAAATTTAGCATCAGAAAACTAAGTGCCGGTGCAGCATCAGTATTAGTTGCAACAAG 
4 2 l TGTGTTGGGAGGGACAACTGTAAAAGCGAACTCTGAGGTTAGTCGTACGGCGACTCCAAG 
4 8 l ATTATCGCGTGATTTAAAAAATAGATTAAGCGATATAGCCATAAGTGGAGATGCCTCATC 
5 4 l AGCCCAAAAAGTTCGAAATCTTCTAAAAGGCGCCTCTGTTGGGGATTTACAGGCATTATT 
6 O l GAGAGGTCTTGATTCAGCAAGGGCTGCGTATGGTAGAGATGATTATTACAATTTATTGAT 
6 6 l GCACCTTTCATCGATGTTAAATGATAAACCTGATGGGGATAGAAGACAATTAAGTTTGGC 
7 2 l TTCATTACTTGTAGATGAAATTGAAAAGCGGATTGCTGATGGAGATAGGTATGCAAAACT 
7 8 l TCTTGAGGCTAAACTTGCAGCTATTAAATCTCAACAAGAAATGCTTAGAGAAAGAGATTC 
8 4 l CCAACTTCGAAATCTAGAGAAGGAGAAAGAACAAGAGCTCACAAAAGCTAAAGATGAGCG 
9 O l TCAAGCTCTTACCGAATCATTCAACAAAACTTTATCAAGATCAACAAAAGAGTATAATAA 
9 6 l ACTAAAAACAGAACTTGCAAAAGAAAAAGAAAAAGCAGCTAAGATGACTAAGGAATTAGC 
l O 2 l AGATAAGCTAAGCAATGCTGAAGCAAGTCGTGATAAAGCCTTTGCAGTATCAAAAGATTT 
l O 8 l AGCAGATAAACTAAGTAGTGCTGAAGCAAGTCGTGATAAAGCTTTTGCAGTATCAAAAGA 
l l 4 l TTTAGCAGATAAATTGGCAGCTAAAACAGCAGAAGCTGAAAAGTTAATGGAAAACGTTGG 
l 2 O l TAGTCTAGACCGCTTGGTAGAGTCTGCAAAACGTGAAATGGCTCAAAAATTAGCAGAAAT 
l 2 6 l TGATCAATTAACTGCTGATAAGGCTAAGGCTGATGCAGAGCTTGCAGCTGCAAATGACAC 
l 3 2 l CATTGCATCACTTCAAACAGAGCTAGAAAAAGCTAAGACAGAGCTTGCTGTTTCAGAGCG 
l 3 8 l TTTGATTGAATCAGGCAAACGTGAAATTGCTGAGCTACAAAAACAAAAAGATGCTTCTGA 
l 4 4 l TAAGGCTTTAGTAGAATCACAAGCTAATGTAGCAGAGCTTGAAAAACAAAAAGCAGCATC 
l 5 O l AGATGCTAAGGTAGCAGAGCTTGAAAAAGAAGTTGAAGCTGCTAAAGCTGAGGTTGCAGA 
l 5 6 l TCTTAAAGCACAATTAGCTAAGAAAGAAGAAGAGCTTGAAGCCGTTAAGAAGGAAAAAGA 
l 6 2 l AGCGCTTGAAGCTAAGATTGAAGAGCTCAAAAAAGCTCATGCTGAGGAACTTTCAAAACT 
l 6 8 l TAAAGAAATGCTTGAGAAGAAAGACCATGCAAATGCAGATCTTCAAGCAGAAATCAATCG 
l 7 4 l CTTGAAGCAAGAGCTAGCTGACAGGATTAAGTCATTGTCACAAGGTGGTCGTGCTTCACA 
l 8 O l AACAAACCCAGGCACTACAACTGCTAAAGCAGGTCAATTGCCATCTACTGGTGAGTCTGC 
l 8 6 l TAACCCATTCTTCACTATTGCAGCTCTTACTGTCATCGCTGGTGCTGGAATGGCTGTGGT 
l 9 2 l GTCTCCTAAACGCAAAGAAAACTAAGCTATTTCCTCTTTCCCCAATGGACAATAGCCGAA 
l 9 8 l ATAATAGAGCGACTATCGTTCTAACACAAAAGCAACAGTCTCCTGTCTGTTGCTTTTTGT 
2 O 4 l GATATTAGGGCTCATCAGTCTAGGCTAATGGTTTTCTGCGCTTTATCTGCA 
[SEQ ID NO. 1 (M-protein (SeM) gene of S. equi)]. The 60 Moreover, the compound de?ned by bases number 452 
open reading frame starts at 341 and continues to base 1934. through approximately 1331 are also preferred (SEQ ID NO 
Preferably, the compound is SEQ ID NO 1. HoWever, also 4). 
Provided are Compounds Which are complementary to SEQ As skilled artisans can appreciate, the DNA compounds 
ID NO 1 0r COIIIPIfIIIIGHIaIY I0 portions 0f SEQ ID NO 1- A exempli?ed above can readily instruct one as to useful, 
preferred portion of SEQ ID NO 1 is that described above as 65 complementary RNA sequences. Any such RNA sequences 
base number 341 to 1943, inclusive (SEQ ID NO 3). are also considered Within the scope of the present invention. 
US 6,458,358 B1 
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In the present disclosure, this group of DNA and RNA 
compounds are termed “nucleic acid compounds”. 
Moreover, cells transfected With a (or multiple copies of 
a) nucleic acid compound of the present invention are 
provided. Preferred is a cell transfected With SEQ ID NO 1 
or a portion thereof. Such cells may be prokaryotic or 
eukaryotic. Preferred cells include: E. coli, S. cerevisiae, and 
Salmonella spp. Also provided are vectors transfected With 
a (or multiple copies of a) nucleic acid compound of the 
present invention. Preferred vectors include poX viruses, 
adenoviruses or other viral vectors. 
The nucleic acid compounds may be obtained by PCR 
using primers as is skill of the art, or from Gen Bank, 
accession number U73162. Vectors and cell lines can also be 
obtained as is skill of the art. 
Moreover, also provided is the amino acid compound: 
15 25 
lMFLRNNKPKFSIRKLS 
SlGTTVKANSEVSRTATPRLSRDLKNR 
GlISGDASSAQKVRNLLKGASVGDLQ 
91DSARAAYGRDDYYNLLMHLSSMLND 
l2lRRQLSLASLLVDEIEKRIADGDRY 
l5lKLAAIKSQQEMLRERDSQLRNLEKE 
lBlTKAKDERQALTESFNKTLSRSTKEY 
2llELAKEKEKAAKMTKELADKLSNAE 
241FAVSKDLADKLSSAEASRDKAFAVS 
271KLAAKTAEAEKLMENVGSLDRLVES 
SOlAQKLAEIDQLTADKAKADAELAAAN 
SSlLQTELEKAKTELAVSERLIESGKRE 
SGlKQKDASDKALVESQANVAELEKQK 
391VAELEKEVEAAKAEVADLKAQLAKK 
421AVKKEKEALEAKIEELKKAHAEELS 
451LEKKDHANADLQAEINRLKQELADR 
481QGGRASQTNPGTTTAKAGQLPSTGE 
5llFTIAALTVIAGAGMAVVSPKRKEN 
Which is SEQ ID NO 2. The present invention also includes 
portions of the above sequence. The most preferred portion 
of the above sequence is: residues 37 to 330 (SEQ ID NO 5) 
hoWever, one skilled in the art recognizes that any especially 
antigenic portion is commercially signi?cant, and is 
included in the scope of the present invention. 
The amino acid compounds can be obtained either by 
overeXpression and puri?cation in microorganisms, or, in 
some cases, by conventional peptide synthesis. 
Therefore, a vaccine for S. equi is provided by the present 
invention. A vaccine Which is administered intranasally or 
orally is a preferred embodiment. A vaccine of the present 
invention can comprise the entire SEQ ID NO 2, or portions 
thereof. 
The vaccines of the present invention can be of any 
pharmaceutically-acceptable formulation. For eXample, 
SEQ ID NO 5 can be incorporated into bilayer vesicles 
(liposomes), in an aqueous medium according to knoWn 
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6 
procedures, such as that described by Debs et al., 265 J. Biol. 
Chem. 10189 (1990). Any available carrier or liposome 
forming lipid may be utiliZed in any formulation Which 
delivers SeM antigen, for eXample, poly-DL-Lactide-co 
glycolide may be utiliZed in an intranasal spray formulation 
Which comprises SEQ ID NO 5. Formulations Which include 
adjuvants Which enhance the delivery of antigen to the 
mucosa, such as small amounts of the Bsubunit of the 
cholera toxin are also Within the scope of the present 
invention. 
The present invention also provides methods to stimulate 
a S. equi-speci?c immune response in horses comprising 
administering a compound of SEQ ID NO 2 or portions 
thereof. Introduction of the antigen nasally or orally is 
preferred. 
Lastly, the present invention provides methods to deter 
mine the presence of S. equi in horses via polymerase chain 
30 
reaction. The polymerase chain reaction diagnostic assay of 
the present invention can be accomplished according to 
knoWn methods so long as primers for the sequence herein 
disclosed are used as some of the starting materials. Methods 
for PCR can be found in many journals and books, for 
instance, the PCR diagnostic methods can be accomplished 
according to Techniques in PCR, PCR, Current Protocols in 
Molecular Biology or Maniatis. As skilled artisans are 
aWare, preferred primers are those Which are at least 50% 
GC content, ideally 19 to 23 base pairs in length, and are not 
capable of annealing to duplicate sections of the target DNA. 
EXAMPLES 
EXample 1 
Cloning, Sequencing and EXpression of SeM 
Chromosomal DNA of S. equi CF32 Was partially 
digested With Tsp 5091 (NeW England Biolabs Inc., Beverly 
US 6,458,358 B1 
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Mass.) and 3—8 kb fragments ligated to )» ZAPII digested 
With EcoRI (Stratagene, LaJolla, Calif.). After packaging 
(Gigapack II) (Stratagene, LaJolla, Calif.) and transfection 
into E. coli XLI-Blue MRF‘ (Stratagene, LaJolla, Calif.) , the 
library Was plated, ampli?ed and stored at —70° C. in 7% 
DMSO. The library Was screened on duplicate nitrocellulose 
discs by using rabbit 216 antiserum (1:4000 dilution) to the 
acid extracted 41 kDa fragment of SeM. Several reactive 
plaques Were screened until all plaques gave a positive 
signal. Proteins in these phage lysates Were separated by 
SDS PAGE and immunoblotted With serum 216. Aplasmid 
containing a 3.5 kb fragment encoding SeM Was excised 
from a positive phage and the resulting plasmid designated 
pSeM01. Nucleotide sequencing Was performed on HindIII, 
Pvu II and Hind III-Pvu II fragments of the S. equi insert in 
pSK by automated cycle sequencing. Sequences Were 
aligned and connected by DNASIS (Hitachi SoftWare Engi 
neering America, Ltd., San Diego, Calif.). SeM Without its 
signal sequence Was subcloned into the Barn H1 site of the 
pET15b (Novagen, Madison, Wis.) expression vector using 
the polymerase chain reaction (PCR) With pSeM01 as tem 
plate and primers SeM-F 
(gcggatcCGAACTCTGAGGTTAGTCGT) (SEQ ID NO 6) 
and SeM-R (gcggatccATAGCTTAGTTTTCTTTGCG) 
(SEQ ID NO 7). The resulting plasmid Was designated 
pSeM02 and transformed into E. coli BL21 (DE3). Recom 
binant SeM Was isolated from a lysate of BL21 by affinity 
chromatography on His-Bind Resin (Novagen, Madison, 
Wis.). 
Analysis of the connected sequences revealed the pres 
ence of one open reading frame of 1605 nucleotides encod 
ing the seM gene (FIG. 1). Translation of seM revealed a 
basic (CH+4.5) preprotein of 535 amino acids of calculated 
molecular mass 58,251 and p1 of 8.67. N terminal amino 
acid sequence (residues 37—52) Was identical to that 
obtained by direct microsequencing of the 41 kDa SeM 
fragment puri?ed from an acid extract of S. equi. The 
predicted amino acid sequence exhibits features typical of 
streptococcal surface proteins. The signal sequence is 36 
residues. The N terminus of the mature protein has a net 
positive charge. The anchor membrane spanning region and 
charged tail sequences are similar to those of other group A 
and C streptococcal sequences. TWo direct repeats (21 
residues) are located betWeen residues 226 and 267. Other 
shorter direct repeats varying in length from 3 to 6 residues 
occur in the carboxy terminal half of the molecule. Analysis 
of the secondary structure of the translated protein shoWs an 
extensive region of alpha helix extendnng approximately 
from residue 120 to 480. The secondary structure prediction 
shoWs turns in the vicinity of residues 120 and 480 to 500. 
Example 2 
Amino Acid Sequence Determination 
Acid extracted SeM (2 mg) puri?ed as described in 
Example 3 Was loaded onto a 2 cm Wide slot on a 1.5 mm 
thick acrylamide (9%) gel for preparative SDS PAGE. The 
gel Was prerun With 0.1 mM thioglycolic acid for 40 mins at 
100 V before loading the protein. FolloWing electrophoresis, 
and electrophoretic transfer to Immobilon P (Millipore), the 
major 41 and 46 kDa fragments of SeM Were identi?ed by 
staining for 1 min. With 0.025% Coomassie blue in 40% 
methanol and 5% glacial acetic acid folloWed by destaining 
for 2 min in 30% methanol and 5% glacial acetic acid. The 
41 kDa band Was excised and microsequence analysis 
performed on a model 477A pulse liquid phase sequencer 
(Applied Bio Systems) at the University of Kentucky Mac 
romolecular Synthesis Laboratory. 
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Example 3 
Protein Extraction 
M-like protein Was extracted from an overnight culture 
(18 h) of S. equi by hot acid extraction (Lance?eld and 
Perlmann. 96 J. Exp. Med. 71 (1952) and adsorbed to a 
column of hydroxyapatite in 10 mM phosphate buffer pH 
7.2. The M-like proteins Were eluted in 0.2 M Na2HPO4, 
desalted on Sephadex G25 and lyophiliZed. The pellet Was 
dissolved in 25% acetonitrile+0.5% tri?uoroacetic acid and 
loaded on a phenyl RP reverse phase column (Bio-Rad, San 
Francisco Calif.) connected to a Waters 650 protein puri? 
cation system (Waters, Marlborough, Mass.). Protein Was 
eluted using a linear gradient of 25—65% acetonitrile+0.5% 
TFA. A dot immunoblot on cellulose nitrate using SeM 
speci?c rabbit antiserum Was used to screen peaks. The peak 
containing SeM protein eluted at a concentration of approxi 
mately 42% acetonitrile. Positive peaks from several runs 
Were pooled and further puri?ed on the same column. 
Puri?ed protein Was lyophiliZed, resuspended in PBS and 
stored in aliquots at —20° C. Mutanolysin extracts of S. equi 
strains Were performed as described previously (Galan and 
Timoney, 26 J. Clin. Microbiol. 1142 (1988). 
Example 4 
Antisera 
Antiserum Was raised against SeM puri?ed by a combi 
nation of hydroxyapatite and reverse-phase chromatogra 
phy. A NeW Zealand White rabbit (216) Was injected sub 
cutaneously With 50 pg SeM in complete Freund’s adjuvant 
folloWed at 3 Week intervals by 2 similar doses emulsi?ed in 
incomplete Freund’s adjuvant. Serum Was harvested at 8 
Weeks. Rabbit 963 Was similarly hyperimmuniZed With 
recombinant SeM from E. coli sonicate. Rabbit Ec Was 
immuniZed With a lysate of E. coli NovaBlue containing 
plasmid pT7 Blue Without an insert. Adult ICR mice Were 
immuniZed With 25 pg SeM puri?ed from E. coli sonicate by 
HIS-Tag chromatography. Puri?ed SeM (25 pg) Was mixed 
With 5 pg mycolic dipeptide (MDP) and alhydrogel (30%) 
and administered subcutaneously in a dose volume of 100 
ml. TWo subcutaneous booster doses containing 25 pg SeM 
but no MDP Were administered 10 and 20 days later. Mice 
Were bled at 28 days. All antisera Were stored at —70° C. until 
used. 
Example 5 
Immunoblotting 
Proteins in streptococcal extracts or puri?ed from E. coli 
sonicate Were separated by SDS-10% polyacrylamide gel 
electrophoresis (PAGE) and electroblotted to a sheet of 
nitrocellulose and incubated in the appropriate antiserum 
diluted 1:200 in PBS and then in peroxidase-conjugated 
protein G (1:4000). Reactive bands Were visualiZed by using 
4-chloro-1-naphthol (0.5 mg/ml) as substrate. 
Rabbit 963 antiserum to recSeM reacted With a 58 kDa 
protein in a mutanolysin extract of S. equi and With a slightly 
larger 60 kDa protein expressed by E. coli BL21 containing 
pSeM02 (FIG. 2). The same protein bands Were recogniZed 
by rabbit 216 antiserum to the 41 kDa fragment of SeM. 
FIG. 3 shoWs the immunoblot pro?les of mutanolysin 
extracts of a series of S. equi isolates collected at different 
times in the US and Europe. Antiserum to recSeM recog 
niZed tWo protein bands of 58 and 56 kDa in all the extracts. 
Example 6 
ELISA 
An acid extracted fragment (41 kDa) of SeM puri?ed by 
preparative electrophoresis on agarose Was used to coat 
Wells (2.5 mg/Well) of polystyrene ELISA plates (Costar, 
US 6,458,358 B1 
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25880, Corning Glass Company, Corning After Wash 
ing and blocking in 0.1 M phosphate buffered saline (PBS) 
containing 0.05 Tween 20 and 1% bovine serum albumin, 
mouse or rabbit sera diluted 1:80 and 1:200 respectively in 
PBS Were added in triplicate to the Wells (100 ml/Well). 
After incubation for 3 hours at 37° C., bound IgG Was 
detected With either peroxidase conjugated protein G 
(114000) or rabbit anti-mouse IgG folloWed by O-phenylene 
diamine (0.0001 mM) solution. Mean OD values of tripli 
cate readings Were blanked against Wells containing antigen 
and PBS. 
Example 7 
Opsonic Assay 
Equine neutrophils Were separated from freshly collected 
hepariniZed horse blood With a discontinuous Percoll gra 
dient Pycock et al., 42 Res. Vet. Sci. 411 (1987). Neutrophils 
from 7 ml of blood Were suspended in RPM1 medium 
(Gibco, Grand Island, NY.) and 80 ml aliquots (6x105 cells) 
added in triplicate to Wells of a 24 Well cell culture cluster 
(Costar, Cambridge, Mass.). Each Well contained a circular 
glass coverslip (12 mm diameter). The cell cluster Was 
incubated for 2 h at 37° C. in 5% CO2 and the cells Washed 
once With PBS to remove non-adherent neutrophils. The test 
organisms (S. equi CF32 and S. zooepia'emicus W60) Were 
groWn overnight at 37 C. in THB With 0.2% yeast extract to 
an OD of 0.6. TWenty ml of culture Was added to 25 ml 
serum and 450 ml RPMI added. After the plate Was gently 
shaken for 30 minutes at 37 C. the coverslips Were Washed 
once With PBS (pH 7.2) ?xed in 10% formalin and stained 
With Giemsa The numbers of neutrophils With associated 
streptococci per 100 cells Were then counted for each serum 
and expressed as a percentage. All assays Were performed in 
triplicate. The differences in the opsonic activities of 
immune and control sera Were evaluated statistically by a 
Student t-test (Unpaired Observations) based on the means 
of three experiments. 
Sera from mice immuniZed With puri?ed recombinant 
SeM shoWed 15 times greater (p<0.01) opsonic activity for 
S. equi than non-immune mouse sera. These sera also 
shoWed strong antibody responses by ELISA to the 41 kDa 
fragment of SeM (Example 6). 
Example 8 
Fibrinogen Binding Assay 
Equine ?brinogen (0.5 mg/Well) Was bound to Wells of 96 
Well polystyrene ELISA plates (Costar). After Washing and 
blocking, recombinant SeM (0.4 mg/Well) Was added in 
triplicate to separate Wells and incubated for 2 hours at 37 C. 
After Washing, 1:80 dilutions of rabbit antisera to the 41 kDa 
fragment of SeM Was added to the appropriate Wells and 
incubated at 37 C. for 2 hours. Control Wells consisted of 
Wells from Which ?brinogen Was omitted and Wells treated 
With sera from the same rabbits before immuniZation. 
Amounts of speci?c rabbit antibody that bound to SeM ?xed 
to ?brinogen Were detected as described under ELISA. 
SeM shoWed strong binding to equine ?brinogen immo 
biliZed on Wells of ELISA plates. Mean ELISA value (:SD) 
for SeM bound to ?brinogen after correction for non-speci?c 
binding of the protein to blocked Well surfaces Was 0.9101. 
The corrected value Was 0.1101 When preimmune sera Were 
used to assay for binding of the streptococcal protein. 
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Example 9 
Nucleotide Sequence Accession Numbers 
The Gen Bank accession number for the nucleotide 
sequence of seM is U73162. 
Example 10 
Homologies 
With the exception of signal and membrane anchor 
sequences, no homology of SeM With group A or G M 
protein sequences in the GenBank database Was detected. 
SeM shoWed some homology betWeen its signal (39% 
identity) and membrane anchor (66% identity) sequences 
With those in the database. 
Example 11 
Presence of SeM-binding Antibodies in Convalescent 
Horses 
Regions of SeM reactive With antibodies in horse sera 
taken 8 Weeks after recovery from strangles are shoWn in 
FIG. 3. Most horses shoWed reponses to epitopes on the 
central region of SeM (residues 170 to 270). Responses of 
individual horses to the N terminal third and carboxy 
terminal regions of SeM Were much more variable. No horse 
responded to peptide 151—166 alone. Linear epitopes rec 
ogniZed by IgA in convalescent (8 Weeks) nasal Washes are 
found on the same region reactive With serum antibody 
(FIG. 4). Multiple epitopes are targeted and, as in the case 
of serum antibodies, there is considerable variation in the 
responses of individual horses. 
Example 12 
ImmuniZations of Non-exposed Yearling Ponies 
TWo groups of 3 yearling Welsh ponies Were immuniZed 
With microencapsulated recombinant fusion peptide of the 
M-protein (SeM, amino acids 231—330) produced in E. coli 
BL21 and With a microencapsulated extract of the host E. 
coli alone. Encapsulated protein (100 pg) Was sprayed into 
each nostril on day 1 using a nasal atomiZer. Booster doses 
of 150 and 350 pg Were given on days 7 and 42, respectively. 
Serum and nasal Washes Were collected at days 1, 7, 21 and 
42 and assayed for SeM-speci?c IgG in serum and IgA in 
nasal Washes, 
Speci?c mucosal IgA responses to SeM Were evident at 
day 21 in 2 of the 3 ponies and in all ponies at day 49. None 
of the 3 control ponies immuniZed With E. coli extract alone 
responded to SeM. No serum antibody responses Were 
detected in any pony. These studies demonstrate the feasi 
bility of selectively-inducing speci?c mucosal antibody 
responses in horses by using a microencapsulated strepto 
coccal peptide. 
Example 13 
PCR Diagnostic Assay 
Nasal sWabs (Precision Dynamic Corp. San Fernando, 
Calif.; Culturette, Baxter Healthcare Corp., Deer?eld, Ill.) 
Were collected from affected and exposed in-contact horses 
1 to 5 days after clinical diagnosis of strangles on farms A, 
B, C, and D. Some horses Were sampled more than once over 
the folloWing 3 Weeks. Nasal Washes Were collected from 
horses at UK farm 15 and 85 days folloWing commingling 
exposure to 2 horses With clinical strangles. All these horses 
developed strangles Within 17 days of commingling expo 
sure. Nasal Washes Were collected by instilling 50 ml 
phosphate buffered saline (pH 7.2) via a 8 mm diameter 
latex tube inserted 15 cm into the nostril and collecting the 
?uid that drained out. The ?uid Was centrifuged at 3000 g 
and the pelleted debris separated for culture and PCR. SWabs 
and nasal Wash pellets Were cultured on Columbia CNA 
US 6,458,358 B1 
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horse blood agar and incubated for 18 hours at 37° C. Beta 
hemolytic colonies Were subcultured and their fermentation 
behavior tested in lactose, sorbitol and trehalose broths. 
Mucoid beta-hemolytic colonies that did not ferment any of 
these sugars Were identi?ed as S. equi. 
DNA for PCR from nasal sWabs and Washes Was prepared 
as folloWs: SWab tips Were placed in 300 pl of sterile Water, 
vorteXed, the tips removed and the ?uid centrifuged at 
14,000 g for 10 minutes. The sediments Were resuspended in 
12 
(bases 239—258) SEQ ID NO 8) and 
5‘-GATTCGGTAAGAGCTTGACG (SeM reverse(bases 
899—918) SEQ ID NO 9). Mineral oil (30 pl) Was added to 
seal the reaction miX. Cycling Was performed as folloWs: 
—92° C. for 2 minutes; 92° C. for 1 minute; 58° C. for 1 
minute; 72° C. for 1 minute (30 times); 72° C. for 5 minutes; 
4° C. ?nal. The PCR products Were separated by ethidium 
bromide agarose gel electrophoresis. The SeM fragment 
ampli?ed With primers SeM6 and 7 Was 679 bp. 
20 pl of K-buffer (1>< Gen Amp Buffer II, Perkin Elmer, 10 _ _ 
05% Tween 20, 100 pig/m1 Proteinase Nasal Wash The PCR detected a 679 bp DNA fragment in 37 spec1 
pellets Were Suspended in an equal Volume of K_buffer_ The mens 'including 14 of 15 that were positive by culture. The 
suspensions Were incubated for 30 minutes at 55° C., boiled Sensmvlty of PCR appears to be much greater than Culture' 
for 5 minutes and then centrifuged for 5 minutes at 14,000 Although the present invention has been fully described, 
g. The reaction miX for PCR in a total volume of 30 pl Was 15 it is to be noted that various changes and modi?cations are 
prepared in Gen Amp Buffer II and contained 2 mM MgCl2, apparent to those skilled in the art Such changes and 
0.2 mM dNTP, 0.5 units Taq polymerase, 0.25 pM SeM6 and modi?cations are to be understood as included Within the 
SeM7 primers, and 2—5 pl sample. The primer sequences scope of the present invention as de?ned by the appended 
Were 5‘-TGCATAAAGAAGTTCCTGTC (SeM7-forward claims. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: l0 
<2 10> SEQ ID NO 1 
<211> LENGTH: 2091 
<2 12> TYPE: DNA 
<213> ORGANISM: Streptococcus equi 
<400> SEQUENCE: l 
agctttctgt cacctgatgg tccttatcaa atactgtaat tgataacttc aaacagccct 60 
gtagagattt tactaacgac atagtatcca tgctaagcgt cacccccttc ataatcctca 120 
cggtatctta ttctatctta aaatttaaga aaagcaagga tatgcactta taatgaaaaa 180 
atagacataa aaaacaataa tatacattct tgcttattaa ataaaaatga caatgtactg 240 
cataaagaag ttcctgtcat taaaataaaa gtgccatgag gttataatag tatggtaaaa 300 
caaaaaagtg tgcccataac gggtagagag gaattgacat atgtttttga gaaataacaa 360 
gccaaaattt agcatcagaa aactaagtgc cggtgcagca tcagtattag ttgcaacaag 420 
tgtgttggga gggacaactg taaaagcgaa ctctgaggtt agtcgtacgg cgactccaag 480 
attatcgcgt gatttaaaaa atagattaag cgatatagcc ataagtggag atgcctcatc 540 
agcccaaaaa gttcgaaatc ttctaaaagg cgcctctgtt ggggatttac aggcattatt 600 
gagaggtctt gattcagcaa gggctgcgta tggtagagat gattattaca atttattgat 660 
gcacctttca tcgatgttaa atgataaacc tgatggggat agaagacaat taagtttggc 720 
ttcattactt gtagatgaaa ttgaaaagcg gattgctgat ggagataggt atgcaaaact 780 
tcttgaggct aaacttgcag ctattaaatc tcaacaagaa atgcttagag aaagagattc 840 
ccaacttcga aatctagaga aggagaaaga acaagagctc acaaaagcta aagatgagcg 900 
tcaagctctt accgaatcat tcaacaaaac tttatcaaga tcaacaaaag agtataataa 960 
actaaaaaca gaacttgcaa aagaaaaaga aaaagcagct aagatgacta aggaattagc 1020 
agataagcta agcaatgctg aagcaagtcg tgataaagcc tttgcagtat caaaagattt 1080 
agcagataaa ctaagtagtg ctgaagcaag tcgtgataaa gcttttgcag tatcaaaaga 1140 
tttagcagat aaattggcag ctaaaacagc agaagctgaa aagttaatgg aaaacgttgg 1200 
tagtctagac cgcttggtag agtctgcaaa acgtgaaatg gctcaaaaat tagcagaaat 1260 
13 
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tgatcaatta 
cattgcatca 
tttgattgaa 
taaggcttta 
agatgctaag 
tcttaaagca 
agcgcttgaa 
taaagaaatg 
cttgaagcaa 
aacaaaccca 
taacccattc 
gtctcctaaa 
ataatagagc 
gatattaggg 
<210> 
<2ll> 
TYPE: 
ORGAN 
Met Phe Leu 
1 
Ala Gly Ala 
Thr Val Lys 
35 
Ser Arg 
50 
Asp 
Ala 
65 
Ser Ser 
Gly Asp Leu 
Tyr Gly Arg 
Leu Asn Asp 
115 
Leu Val 
130 
Leu 
Ala 
145 
Lys Leu 
Met Leu Arg 
Glu Gln Glu 
Phe Asn 
195 
Ser 
Thr 
210 
Lys Glu 
Glu Leu Ala 
actgctgata 
cttcaaacag 
tcaggcaaac 
gtagaatcac 
gtagcagagc 
caattagcta 
gctaagattg 
cttgagaaga 
gagctagctg 
ggcactacaa 
ttcactattg 
cgcaaagaaa 
gactatcgtt 
ctcatcagtc 
PRT 
ISM: 
SEQUENCE: 
Arg 
Ala 
20 
Ala 
Leu 
Ala 
Gln 
Asp 
100 
Lys 
Asp 
Leu 
Glu 
Leu 
180 
Lys 
Leu 
Asp 
SEQ ID NO 2 
LENGTH: 534 
aggctaaggc 
agctagaaaa 
gtgaaattgc 
aagctaatgt 
ttgaaaaaga 
agaaagaaga 
aagagctcaa 
aagaccatgc 
acaggattaa 
ctgctaaagc 
cagctcttac 
actaagctat 
ctaacacaaa 
taggctaatg 
tgatgcagag 
agctaagaca 
tgagctacaa 
agcagagctt 
agttgaagct 
agagcttgaa 
aaaagctcat 
aaatgcagat 
gtcattgtca 
aggtcaattg 
tgtcatcgct 
ttcctctttc 
agcaacagtc 
gttttctgcg 
Streptococcus equi 
2 
Asn 
Ser 
Asn 
Lys 
Gln 
Ala 
85 
Asp 
Pro 
Glu 
Glu 
Arg 
165 
Thr 
Thr 
Ala 
Lys 
Asn Lys Pro 
Val Leu Val 
Glu Val 
40 
Ser 
Asn Arg Leu 
Lys Val 
70 
Arg 
Leu Leu Arg 
Tyr Tyr Asn 
Asp Gly Asp 
120 
Ile Glu 
135 
Lys 
Ala 
150 
Lys Leu 
Asp Ser Gln 
Lys Ala Lys 
Leu Ser Arg 
200 
Glu 
215 
Lys Lys 
Leu Ser Asn 
Lys Phe Ser 
Ala 
25 
Thr Ser 
Ser Arg Thr 
Ser Asp Ile 
Leu 
75 
Asn Leu 
Leu 
90 
Gly Asp 
Leu Leu Met 
105 
Arg Arg Gln 
Arg Ile Ala 
Ala Ala Ile 
155 
Asn Leu Arg 
170 
Asp Glu 
185 
Arg 
Ser Thr Lys 
Glu Lys Ala 
Ala Glu Ala 
cttgcagctg 
gagcttgctg 
aaacaaaaag 
gaaaaacaaa 
gctaaagctg 
gccgttaaga 
gctgaggaac 
cttcaagcag 
caaggtggtc 
ccatctactg 
ggtgctggaa 
cccaatggac 
tcctgtctgt 
ctttatctgc 
Ile Arg Lys 
Val Leu Gly 
30 
Ala Thr 
45 
Pro 
Ala Ile Ser 
Lys Gly Ala 
Ser Ala Arg 
Ser 
110 
His Leu 
Ser Leu 
125 
Leu 
Asp 
140 
Gly Asp 
Lys Ser Gln 
Leu Glu Lys 
Gln Ala Leu 
190 
Glu Tyr Asn 
205 
Ala 
220 
Lys Met 
Ser Arg Asp 
caaatgacac 
tttcagagcg 
atgcttctga 
aagcagcatc 
aggttgcaga 
aggaaaaaga 
tttcaaaact 
aaatcaatcg 
gtgcttcaca 
gtgagtctgc 
tggctgtggt 
aatagccgaa 
tgctttttgt 
a 
Leu Ser 
15 
Gly Thr 
Arg Leu 
Gly Asp 
Val 
80 
Ser 
Ala 
95 
Ala 
Ser Met 
Ala Ser 
Arg Tyr 
Gln Glu 
160 
Glu 
175 
Lys 
Thr Glu 
Lys Leu 
Thr Lys 
Lys Ala 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1740 
1800 
1860 
1920 
1980 
2040 
2091 
15 
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225 
Phe Ala Val 
Ser Arg Asp 
Ala Ala Lys 
275 
Leu Asp 
290 
Arg 
Ala 
305 
Glu Ile 
Leu Ala Ala 
Lys Ala Lys 
Glu 
355 
Lys Arg 
Ala Leu Val 
370 
Ala 
385 
Ala Ser 
Ala Lys Ala 
Glu Glu Leu 
Ile Glu Glu 
435 
Glu Met 
450 
Leu 
Ile 
465 
Asn Arg 
Gln Gly Gly 
Ala Gly Gln 
Ile Ala Ala 
515 
Pro Lys 
530 
Arg 
TYPE: 
atgtttttga gaaataacaa 
tcagtattag 
agtcgtacgg 
ataagtggag 
ggggatttac 
gattattaca 
Ser 
Lys 
260 
Thr 
Leu 
Asp 
Ala 
Thr 
340 
Ile 
Glu 
Asp 
Glu 
Glu 
420 
Leu 
Glu 
Leu 
Arg 
Leu 
500 
Leu 
Lys 
DNA 
SEQUENCE: 
ttgcaacaag 
cgactccaag 
atgcctcatc 
aggcattatt 
atttattgat 
Lys 
245 
Ala 
Ala 
Val 
Gln 
Asn 
325 
Glu 
Ala 
Ser 
Ala 
Val 
405 
Ala 
Lys 
Lys 
Lys 
Ala 
485 
Pro 
Thr 
Glu 
SEQ ID NO 3 
LENGTH: 1603 
3 
230 
Asp Leu Ala 
Phe Ala Val 
Glu Ala Glu 
280 
Glu Ser Ala 
295 
Leu Thr Ala 
310 
Asp Thr Ile 
Leu Ala Val 
Glu Gln 
360 
Leu 
Gln Ala 
375 
Asn 
Lys Val Ala 
390 
Ala Asp Leu 
Val Lys Lys 
His 
440 
Lys Ala 
Lys Asp His 
455 
Gln 
470 
Glu Leu 
Ser Gln Thr 
Ser Thr Gly 
Val Ile Ala 
520 
Asn 
gccaaaattt 
tgtgttggga 
attatcgcgt 
agcccaaaaa 
gagaggtctt 
gcacctttca 
235 
Asp Lys Leu 
250 
Ser 
265 
Lys Asp 
Lys Leu Met 
Lys Arg Glu 
Ala 
315 
Asp Lys 
Ala Ser Leu 
330 
Ser Glu 
345 
Arg 
Lys Gln Lys 
Val Ala Glu 
Glu Glu 
395 
Leu 
Ala 
410 
Lys Gln 
Glu 
425 
Lys Glu 
Ala Glu Glu 
Ala Asn Ala 
Ala Asp Arg 
475 
Pro 
490 
Asn Gly 
Glu 
505 
Ser Ala 
Gly Ala Gly 
ORGANISM: Streptococcus equi 
agcatcagaa 
gggacaactg 
gatttaaaaa 
gttcgaaatc 
gattcagcaa 
tcgatgttaa 
Ser Ser Ala 
Leu Ala Asp 
270 
Glu Asn Val 
285 
Met 
300 
Ala Gln 
Lys Ala Asp 
Gln Thr Glu 
Ile Glu 
350 
Leu 
Ala 
365 
Asp Ser 
Leu Glu 
380 
Lys 
Lys Glu Val 
Leu Ala Lys 
Ala Glu 
430 
Leu 
Ser 
445 
Leu Lys 
Asp Leu Gln 
460 
Ile Lys Ser 
Thr Thr Thr 
Phe 
510 
Asn Pro 
Met Ala 
525 
Val 
aactaagtgc 
taaaagcgaa 
atagattaag 
ttctaaaagg 
gggctgcgta 
atgataaacc 
240 
Glu 
255 
Ala 
Lys Leu 
Gly Ser 
Lys Leu 
Ala Glu 
320 
Leu Glu 
335 
Ser Gly 
Asp Lys 
Gln Lys 
Glu Ala 
400 
Lys Glu 
415 
Ala Lys 
Leu Lys 
Ala Glu 
Ser 
480 
Leu 
Ala 
495 
Lys 
Phe Thr 
Val Ser 
cggtgcagca 
ctctgaggtt 
cgatatagcc 
cgcctctgtt 
tggtagagat 
tgatggggat 
60 
120 
180 
240 
300 
360 
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<2 10> SEQ ID NO 5 
<211> LENGTH: 294 
<212> TYPE: PRT 
<213> ORGANISM: Streptococcus equi 
<400> SEQUENCE: 5 
Asn Ser Glu Val Ser Arg Thr Ala Thr Pro Arg Leu Ser Arg Asp Leu 
1 5 10 15 
Lys Asn Arg Leu Ser Asp Ile Ala Ile Ser Gly Asp Ala Ser Ser Ala 
20 25 30 
Gln Lys Val Arg Asn Leu Leu Lys Gly Ala Ser Val Gly Asp Leu Gln 
Ala Leu Leu Arg Gly Leu Asp Ser Ala Arg Ala Ala Tyr Gly Arg Asp 
50 55 60 
Asp Tyr Tyr Asn Leu Leu Met His Leu Ser Ser Met Leu Asn Asp Lys 
65 70 75 80 
Pro Asp Gly Asp Arg Arg Gln Leu Ser Leu Ala Ser Leu Leu Val Asp 
85 90 95 
Glu Ile Glu Lys Arg Ile Ala Asp Gly Asp Arg Tyr Ala Lys Leu Leu 
100 105 110 
Glu Ala Lys Leu Ala Ala Ile Lys Ser Gln Gln Glu Met Leu Arg Glu 
115 120 125 
Arg Asp Ser Gln Leu Arg Asn Leu Glu Lys Glu Lys Glu Gln Glu Leu 
130 135 140 
Thr Lys Ala Lys Asp Glu Arg Gln Ala Leu Thr Glu Ser Phe Asn Lys 
145 150 155 160 
Thr Leu Ser Arg Ser Thr Lys Glu Tyr Asn Lys Leu Lys Thr Glu Leu 
165 170 175 
Ala Lys Glu Lys Glu Lys Ala Ala Lys Met Thr Lys Glu Leu Ala Asp 
180 185 190 
Lys Leu Ser Asn Ala Glu Ala Ser Arg Asp Lys Ala Phe Ala Val Ser 
195 200 205 
Lys Asp Leu Ala Asp Lys Leu Ser Ser Ala Glu Ala Ser Arg Asp Lys 
210 215 220 
Ala Phe Ala Val Ser Lys Asp Leu Ala Asp Lys Leu Ala Ala Lys Thr 
225 230 235 240 
Ala Glu Ala Glu Lys Leu Met Glu Asn Val Gly Ser Leu Asp Arg Leu 
245 250 255 
Val Glu Ser Ala Lys Arg Glu Met Ala Gln Lys Leu Ala Glu Ile Asp 
260 265 270 
Gln Leu Thr Ala Asp Lys Ala Lys Ala Asp Ala Glu Leu Ala Ala Ala 
275 280 285 
Asn Asp Thr Ile Ala Ser 
290 
<2 10> SEQ ID NO 6 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Streptococcus equi 
<400> SEQUENCE: 6 
gcggatccga actctgaggt tagtcgt 
<2l0> SEQ ID NO 7 
<211> LENGTH: 28 
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TYPE: DNA 
ORGANISM: Streptococcus equi 
SEQUENCE: 7 
gcggatccat agcttagttt tctttgcg 
SEQ ID NO 8 
LENGTH: 20 
TYPE: DNA 
ORGANISM: Streptococcus equi 
SEQUENCE: 8 
tgcataaaga agttcctgtc 
SEQ ID NO 9 
LENGTH: 20 
TYPE: DNA 
ORGANISM: Streptococcus equi 
SEQUENCE: 9 
gattcggtaa gagcttgacg 
SEQ ID NO 10 
LENGTH: 1889 
TYPE: DNA 
ORGANISM: Streptococcus equi 
SEQUENCE: 10 
tacattcttg cttattaaat aaaaatgaca atgtactgca taaagaagtt cctgtcatta 
aaataaaagt gccatgaggt tataatagta tggtaaaaca aaaaagtgtg cccataacgg 
gtagagagga attgacatat gtttttgaga aataacaagc caaaatttag catcagaaaa 
ctaagtgccg gtgcagcatc agtattagtt gcaacaagtg tgttgggagg gacaactgta 
aaagcgaact ctgaggttag tcgtacggcg actccaagat tatcgcgtga tttaaaaaat 
agattaagcg atatagccat aagtggagat gcctcatcag cccaaaaagt tcgaaatctt 
ctaaaaggcg cctctgttgg ggatttacag gcattattga gaggtcttga ttcagcaagg 
gctgcgtatg gtagagatga ttattacaat ttattgatgc acctttcatc gatgttaaat 
gataaacctg atggggatag aagacaatta agtttggctt cattacttgt agatgaaatt 
gaaaagcgga ttgctgatgg agataggtat gcaaaacttc ttgaggctaa acttgcagct 
attaaatctc aacaagaaat gcttagagaa agagattccc aacttcgaaa tctagagaag 
gagaaagaac aagagctcac aaaagctaaa gatgagcgtc aagctcttac cgaatcattc 
aacaaaactt tatcaagatc aacaaaagag tataataaac taaaaacaga acttgcaaaa 
gaaaaagaaa aagcagctaa gatgactaag gaattagcag ataagctaag caatgctgaa 
gcaagtcgtg ataaagcctt tgcagtatca aaagatttag cagataaact aagtagtgct 
gaagcaagtc gtgataaagc ttttgcagta tcaaaagatt tagcagataa attggcagct 
aaaacagcag aagctgaaaa gttaatggaa aacgttggta gtctagaccg cttggtagag 
tctgcaaaac gtgaaatggc tcaaaaatta gcagaaattg atcaattaac tgctgataag 
gctaaggctg atgcagagct tgcagctgca aatgacacca ttgcatcact tcaaacagag 
ctagaaaaag ctaagacaga gcttgctgtt tcagagcgtt tgattgaatc aggcaaacgt 
gaaattgctg agctacaaaa acaaaaagat gcttctgata aggctttagt agaatcacaa 
gctaatgtag cagagcttga aaaacaaaaa gcagcatcag atgctaaggt agcagagctt 
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20 
20 
60 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
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-continued 
gaaaaagaag ttgaagctgc taaagctgag gttgcagatc ttaaagcaca attagctaag 1380 
aaagaagaag agcttgaagc cgttaagaag gaaaaagaag cgcttgaagc taagattgaa 1440 
gagctcaaaa aagctcatgc tgaggaactt tcaaaactta aagaaatgct tgagaagaaa 1500 
gaccatgcaa atgcagatct tcaagcagaa atcaatcgct tgaagcaaga gctagctgac 1560 
aggattaagt cattgtcaca aggtggtcgt gcttcacaaa caaacccagg cactacaact 1620 
gctaaagcag gtcaattgcc atctactggt gagtctgcta acccattctt cactattgca 1680 
gctcttactg tcatcgctgg tgctggaatg gctgtggtgt ctcctaaacg caaagaaaac 1740 
taagctattt cctctttccc caatggacaa tagccgaaat aatagagcga ctatcgttct 1800 
aacacaaaag caacagtctc ctgtctgttg ctttttgtga tattagggct catcagtcta 1860 
ggctaatggt tttctgcgct ttatctgca 1889 
20 
What is claimed is: 4. A composition comprising the polypeptide of claim 3 
1, An isolated polypeptide from horse streptococcal Com- further comprising the B-subunit of the cholera toXin. 
prising SEQ ID N();2_ 5. A composition comprising the polypeptide of claim 2 
2' An~ 1 t d 1 t~d f h t t 1 _ incorporated into a liposome. _ _ 
prising 51155511?) 6p 1 6 mm Orse S rep OCOCCa Com 25 6. A composition comprising the polypeptide of claim 5 
3' A Composition Comprising the polypeptide of Claim 1 further comprising the B-subunit of Cholera TOXlIl. 
incorporated into aliposome. * * * * * 
